In conclusion, the pharmacological inhibition of the RANKL/RANK interaction with anti-RANKL in a mouse model of DMD reduces the cardiac hypertrophy inherent to the disease and maintains systolic function. This evidence concerns the gene TNFRSF11A and cardiac hypertrophy.